Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGD | P52209 | 3/20 | 0.53 |
| ▸ | MPI | P34949 | 1/20 | 0.53 |
| ▸ | PGK1 | P00558 | 1/20 | 0.47 |
| ▸ | PGK2 | P07205 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL638724 | 1.00 | PGD (0.53) | PGDMPIPGK1PGK2LMNA | |
| SCHEMBL435808 | 1.00 | PGD (0.53) | PGDMPIPGK1PGK2LMNA | |
| SCHEMBL453487 | 1.00 | PGD (0.53) | PGDMPIPGK1PGK2LMNA | |
| Ribitol SCHEMBL28092351 | 1.00 | PGD (0.53) | PGDMPIPGK1PGK2LMNA | |
| SCHEMBL2767073 | 1.00 | PGD (0.53) | PGDMPIPGK1PGK2LMNA | |
| SCHEMBL28129954 | 1.00 | PGD (0.53) | PGDMPIPGK1PGK2LMNA | |
| SCHEMBL468450 | 1.00 | PGD (0.53) | PGDMPIPGK1PGK2LMNA | |
| SCHEMBL2766970 | 1.00 | PGD (0.53) | PGDMPIPGK1PGK2LMNA | |
| SCHEMBL21610 | 1.00 | PGD (0.53) | PGDMPIPGK1PGK2LMNA | |
| SCHEMBL7861936 | 0.98 | PGD (0.52) | PGDMPIPGK1PGK2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 638 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085296-A1 | PROPAGATOR CELLS AND METHODS FOR PROPAGATING PHAGE, IN PARTICULAR FOR DELIVERING CRISPR-CAS COMPONENTS VIA PROBIOTIC ORGANISMS | SNIPR TECH LTD (GB) | 2026-03-26 | — | — | US | claimed |
| EP-3362089-B1 | IMMUNOGENIC COMPOSITIONS AGAINST S. AUREUS | SANOFI PASTEUR (FR) | 2023-12-06 | — | — | EP | claimed |
| WO-2022114735-A1 | QUALITY EVALUATION METHOD FOR PROCESS OF PURIFYING PRP ANTIGEN OF HAEMOPHILUS INFLUENZAE TYPE B | 주식회사 엘지화학 | 2022-06-02 | — | — | WO | claimed |
| CN-108367062-B | Immunogenic compositions against staphylococcus aureus | 赛诺菲巴斯德有限公司 | 2022-05-06 | — | — | CN | claimed |
| EP-3907238-A1 | METHOD FOR ISOLATING AN IMMUNOGLOBULIN A FRACTION AND USE OF SUCH FRACTION | PreviPharma Consulting GmbH (DE) | 2021-11-10 | — | — | EP | claimed |
| US-11040087-B2 | Therapeutic agent for diseases associated with abnormalities in dystroglycan sugar chain modification and method for assaying associated enzyme | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2021-06-22 | — | — | US | claimed |
| WO-2020218949-A1 | METHOD FOR PREPARING A CONJUGATE HAEMOPHILUS B-TYPE VACCINE | ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ УНИТАРНОЕ ПРЕДПРИЯТИЕ "САНКТ-ПЕТЕРБУРГСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ВАКЦИН И СЫВОРОТОК И ПРЕДПРИЯТИЕ ПО ПРОИЗВОДСТВУ БАКТЕРИЙНЫХ ПРЕПАРАТОВ" ФЕДЕРАЛЬНОГО МЕДИКО- БИОЛОГИЧЕСКОГО АГЕНТСТВА | 2020-10-29 | — | — | WO | claimed |
| US-10772946-B2 | Immunogenic compositions against S. aureus | SANOFI PASTEUR (FR) | 2020-09-15 | — | — | US | claimed |
| US-20200188491-A1 | Therapeutic Agent For Diseases Associated With Abnormalities In Dystroglycan Sugar Chain Modification And Method For Assaying Associated Enzyme | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2020-06-18 | — | — | US | claimed |
| EP-3665272-A1 | PROPAGATOR CELLS AND METHODS FOR PROPAGATING PHAGE, IN PARTICULAR FOR DELIVERING CRISPR-CAS COMPONENTS VIA PROBIOTIC ORGANISMS | Snipr Technologies Limited (GB) | 2020-06-17 | — | — | EP | claimed |
| WO-1993004183-A1 | PROCESS FOR CONVERTING LIPID-CONTAINING BACTERIAL CAPSULAR POLYSACCHARIDE INTO LIPID-FREE POLYSACCHARIDE | MERCK & CO., INC. (US) | 1993-03-04 | — | — | WO | claimed |
| EP-0528635-A1 | Process for converting lipid-containing polysaccharide into lipid-free polysaccharide | MERCK & CO. INC. (US) | 1993-02-24 | — | — | EP | claimed |
| US-4761283-A | REDUCTIVE AMINATION, ANTIBODIES | THE UNIVERSITY OF ROCHESTER (US) | 1988-08-02 | — | — | US | claimed |
| EP-0080021-B1 | HAEMOPHILUS INFLUENZAE TYPE B AND PERTUSSIS OUTER MEMBRANE COMPONENT COMBINED VACCINE | AMERICAN CYANAMID COMPANY (US) | 1986-02-26 | — | — | EP | claimed |
| US-4474758-A | Haemophilus influenzae type b and pertussis outer membrane component combined vaccine | AMERICAN CYANAMID COMPANY (US) | 1984-10-02 | — | — | US | claimed |
| EP-0101562-A2 | Combined haemophilus influenzae and diphtheria, pertussis, tetanus vaccine | AMERICAN CYANAMID COMPANY (US) | 1984-02-29 | — | — | EP | claimed |
| EP-0080021-A2 | Haemophilus influenzae type B and pertussis outer membrane component combined vaccine | AMERICAN CYANAMID COMPANY (US) | 1983-06-01 | — | — | EP | claimed |
| EP-0031708-A2 | Cephalosporin derivatives, processes for their manufacture, pharmaceutical compositions containing them and intermediates therefor | ICI PHARMA (FR) | 1981-07-08 | — | — | EP | claimed |
| US-4220717-A | Isolation and purification of polyribosyl ribitol phosphate from Haemophilus influenzae type b. | AMERICAN CYANAMID COMPANY (US) | 1980-09-02 | — | — | US | claimed |
| US-4196192-A | POLYRIBOSYL RIBITOL PHOSPHATE, B. PERTUSSIS ANTIGEN | AMERICAN CYANAMID COMPANY (US) | 1980-04-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085296-A1 | PROPAGATOR CELLS AND METHODS FOR PROPAGATING PHAGE, IN PARTICULAR FOR DELIVERING CRISPR-CAS COMPONENTS VIA PROBIOTIC ORGANISMS | CASR, HAVCR2, TLR2 | PGD 3800/4885MPI 4197/4885PGK1 3188/4885 |
| US-11040087-B2 | Therapeutic agent for diseases associated with abnormalities in dystroglycan sugar chain modification and method for assaying associated enzyme | MPDU1, GPI, GMDS | PGD 27/4885MPI 22/4885PGK1 731/4885 |
| US-20200188491-A1 | Therapeutic Agent For Diseases Associated With Abnormalities In Dystroglycan Sugar Chain Modification And Method For Assaying Associated Enzyme | MPDU1, GPI, GMDS | PGD 27/4885MPI 22/4885PGK1 731/4885 |
| US-10772946-B2 | Immunogenic compositions against S. aureus | CD4, CSGALNACT1, B3GNT2 | PGD 114/4885MPI 483/4885PGK1 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.